🟠 Moderate Evidence
An estimated 1.7 billion people worldwide carry Mycobacterium tuberculosis, yet only 5–10% of infected individuals develop active tuberculosis disease during their lifetime. Identifying immune markers that predict disease progression could transform TB control by enabling earlier intervention in vulnerable populations before symptoms emerge, according to research outlined by Dr. Anne O’Garra, head of the Immunoregulation Laboratory at the Francis Crick Institute in London.
Key takeaways
- Only 5–10% of people infected with Mycobacterium tuberculosis progress to active TB, but identifying who will develop disease remains a major challenge
- Specific immune response patterns may distinguish people who naturally control infection from those at risk of progression
- Early biomarker discovery could enable preventive interventions before clinical TB develops, potentially reducing the global TB burden
Global TB burden: infection versus active disease
Proportion of TB-infected population progressing to active disease, with intervention opportunity window
Source: Francis Crick Institute immunological research framework | Georgian Medical Journal News
The hidden majority: why some control infection and others don’t
The biological mechanisms that distinguish people who contain M. tuberculosis from those who develop progressive disease remain poorly understood. Dr. Anne O’Garra’s laboratory at the Francis Crick Institute focuses on characterizing immune system responses to infection, with the aim of identifying protective versus pathogenic immune signatures.
This distinction matters clinically: latent TB infection (LTBI) is asymptomatic and non-transmissible, yet approximately 5–10% of LTBI-positive individuals—roughly 156–311 million people based on current global prevalence—will eventually develop active TB disease. Current diagnostic tools cannot reliably predict which infected individuals will progress, forcing clinicians to make preventive treatment decisions based on risk factors rather than individual immune status.
Immune biomarkers as predictive tools
Emerging evidence suggests that specific immune response patterns—including T-cell phenotypes, cytokine profiles, and antibody signatures—may serve as biomarkers for disease progression risk. Dr. O’Garra’s work emphasizes characterizing how the immune system responds to M. tuberculosis antigens in individuals who remain healthy versus those who develop clinical TB.
Identifying such immune signatures could enable stratified clinical assessment of LTBI-positive individuals. Rather than treating all LTBI cases empirically, clinicians could use immune biomarkers to target preventive therapy to those at highest progression risk, potentially improving treatment outcomes and reducing unnecessary medication exposure in individuals who would naturally control infection.
“The big question has always been what distinguishes people who control the infection from those who don’t.” Understanding these immune differences is essential for developing earlier intervention strategies.
— Dr. Anne O’Garra, Immunoregulation Laboratory, Francis Crick Institute (Research framework, 2026)
Clinical and public health implications
If validated immune biomarkers can predict TB progression, the implications extend across TB control policy and clinical practice. Current guidelines recommend LTBI treatment for specific risk groups—people living with HIV, recent TB contacts, healthcare workers, and immunocompromised individuals—but individual immune status is not typically considered. Biomarker-guided risk stratification could refine these recommendations and improve efficiency of TB prevention programs globally.
For high-burden countries with limited resources, such tools could prioritize preventive treatment to those most likely to benefit, reducing costs and medication burden. Furthermore, understanding the immunological basis of natural TB resistance could inform vaccine design and development of immunotherapeutic interventions that enhance protective immunity.
What this means
Frequently asked questions
What is the difference between TB infection and TB disease?
TB infection (latent TB) means Mycobacterium tuberculosis bacteria are present in the body but controlled by the immune system—the person has no symptoms and cannot transmit TB to others. TB disease occurs when bacteria multiply uncontrolled, causing symptoms like persistent cough, fever, and weight loss, and can spread to others. Approximately 85–95% of infected people naturally control the infection and never develop symptoms.
How might immune biomarkers improve TB prevention?
Currently, decisions about preventive TB treatment rely on demographic and epidemiological risk factors (occupation, TB exposure, HIV status). Immune biomarkers could enable direct assessment of an individual’s immune capacity to control infection, allowing clinicians to identify the 5–10% at genuine progression risk. This personalized approach could reduce unnecessary preventive treatment in immunologically protected individuals while ensuring those at highest risk receive therapy.
What specific immune markers are being studied for TB progression?
Researchers are investigating multiple immune signatures, including T-cell populations (particularly CD4+ and CD8+ T-cell phenotypes), cytokine profiles (such as IFN-gamma and IL-10), antibody responses, and metabolic markers of immune activation. The Immunoregulation Laboratory at the Francis Crick Institute focuses on characterizing protective versus pathogenic immune responses to identify which patterns distinguish TB-resistant from TB-susceptible individuals.
The pursuit of immune biomarkers for TB progression represents a paradigm shift toward precision TB prevention. As Dr. O’Garra’s research team continues to characterize the immunological basis of TB resistance, the field moves closer to identifying which infected individuals truly need preventive intervention—enabling more effective, equitable, and efficient TB control globally.
Was this article helpful?
Disclaimer. This article is health journalism intended for general information and education. It is not medical advice and is not a substitute for professional diagnosis or treatment. Always consult a qualified healthcare provider about your individual circumstances. Full disclaimer →
Related Coverage
Editorial standards. This article was produced under the GMJ News editorial process, with oversight by the GMJ Editorial Board. Our editorial process. Spotted an error? Contact the editorial team.
